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Abstract
The following metabolites of sulfadiazine (S) were isolated from monkey urine by preparative HPLC: 5- 
hydroxysulfadiazine (50H), 4-hydroxysulfadiazine (40H) and the glucuronide (SOHgluc) and sulfate conjugate of 
50H  (50Hsulf). The compounds were identified by NMR, mass and infrared spectrometry and hydrolysis by 
/3-glucuronidase. The analysis of S, the hydroxymetabolites (40H, 50H) and conjugates N4-acetylsulfadiazine 
(N4), SOHgluc and 50Hsulf in human and monkey plasma and urine samples was performed using reversed-phase 
gradient HPLC with UV detection. In plasma, S and N4 could be detected in high concentrations, whereas the other 
metabolites were present in only minute concentrations. In urine, S, the metabolites and conjugates were present. 
The limit of quantification of the compounds in plasma varies between 0.2 and 0.6 /¿g/ml (S 0.31, N4 0.40, 40H 
0.20, 50H 0.37, SOHgluc 0.33 and SOHsulf 0.57 ¿tg/ml). In urine it varies between 0.6 and 1.1 /¿g/ml (S 0.75, N4 
0.80, 40H 0.60, 50H 0.80, SOHgluc 0.80 and SOHsulf 1.1 ¿¿g/ml). The method was applied to studies with healthy 
human subjects and Rhesus monkeys. The metabolites 5OH, SOHgluc and 50Hsulf were present in Rhesus 
monkey and not in man. Preliminary results of studies of metabolism and pharmacokinetics in Rhesus monkey and 
man are presented.
1« In tro d u c tio n
Sulfadiazine is used for the prophylaxis and 
treatment of toxoplasmosis gondii infection and 
bacterial infections, e.g., due to Pneumocystis 
carinii [1,2]. The known metabolism of sul­
* Corresponding author, at address a.
fadiazine (benzenesulfonamide-4-amino-N-pyrî-
midine; CAS No. 68-35-9; S) involves acétylation 
and oxidation at the N4-nitrogen atom, leading 
to N4-acetylsulfadiazine (N4) and N 4-hydroxy- 
sulfadiazine (N4OH). The hydroxylamines of 
sulfonamides are thought to be responsible for 
the occurrence of side-effects of long-term 
prophylactic treatment of Pneumocystis carinii
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pneumonia in HIV-positive patients [1]. Hy­
droxylation also takes place at the C4-carbon of 
the pyrimidine ring, leading to 4-hydroxy- 
sulfadiazine (40H ), and at the C5-carbon, lead­
ing to 5-hydroxysulfadiazine (50H ). The hy­
droxy metabolites can be conjugated with 
glucuronic acid and sulfate [3-6]. This metabolic 
picture of sulfadiazine, as shown in Fig. 1, is 
obtained by means of TLC with detection re­
agents and isocratic HPLC analysis [3-5]. The 
metabolism of sulfonamides is species depen­
dent; acétylation is the main pathway in man, but 
non-existent in dog, and oxidation mainly occurs 
in turtle, cow, horse, etc. [5,6].
Recently, we explored the pharmacokinetics of 
sulfadiazine in Rhesus monkeys (Macaca mulat­
to) and human volunteers by gradient HPLC and 
observed novel conjugates of the hydroxy-
sulfadiazines. The aims of this investigation were
(a) to isolate hydroxy metabolites with their 
conjugates of sulfadiazine from monkey urine,
(b) to develop a gradient HPLC method for the 
determination of sulfadiazine, its hydroxy metab­
olites and novel conjugates and (c) to obtain 
preliminary results of studies of the metabolism 
and pharmacokinetics of S in Rhesus monkey 
and humans.
2. Experimental
2.1. Chemicals
S and N4 were obtained from Astra (Sodertal- 
je, Sweden). The metabolites 40H  and 50H , 
were isolated from monkey urine and were pure
HO—N
4-Hydroxysulfadiazine
N4-hydroxysulfadiazine
Sulfadiazine
I
5-Hydroxysulfadiazine
CHy
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Fig. 1. Structures of sulfadiazine and its metabolites.
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by HPLC. All reagents were of analytical-re- 
agent grade from Merck (Darmstadt, Germany). 
Amberlite XAD-2 absorption resin and Celite 
545 were obtained from Fluka (Perstorp Ana­
lytical, Oud Beyerland, Netherlands).
2.2. Subject and monkeys
A single oral dose of 500 mg S was adminis­
tered to one healthy human subject (male, 35 
years old, 85 kg, slow acetylator of sulfonamides) 
with 100 ml of tap water after an overnight fast. 
The study had the approval of the hospital ethics 
committee and informed consent was obtained 
from the volunteer.
Rhesus monkeys were obtained from the Cen­
tral Animal Laboratory, University of Nijmegen 
and the Laboratory Animals Breeding Ex­
perimental Farm of Shunde Guangdong (Beijing, 
China). One Rhesus monkey (female, 5 years old 
and weighing about 5 kg) was housed in a 
metabolic cage and fed orally with 50 mg/kg of 
sulfadiazine and serial plasma and urine samples 
were collected for 2 days. Three Rhesus monkeys 
(female, 4-5 years old and weighing about 5 kg) 
obtained from the Central Animal Laboratory, 
University of Nijmegen, were housed in a meta­
bolic cage and fed orally for 5 days with 50 
mg/kg of sulfadiazine and all urine was collected 
for 6 days. The study had the approval of the 
ethics committee of the Animal Laboratory.
2.3. Sampling
Blood samples of 2 ml were drawn from the 
volunteer and collected in heparinized Eppen- 
dorf vials (2 ml) at regular time intervals during 
2 days after administration by means of fingertip 
puncture with Monolet lancets (Monoject, St. 
Louis, MO, USA). After centrifuging at 3000 g 
for 5 min, plasma samples were stored at -20°C  
pending analysis.
Urine was collected from untimed voiding. 
The total time of sample collection was 96 h. 
Three samples of 7 ml of each void were stored 
at -20°C pending analysis.
Blood samples of 2 ml were drawn from the
monkey by puncture of the vena mediana and 
collected in heparinized Eppendorf vials at 0.1, 2, 
3, 4, 5, 6, 7, 8, 10, 12, 24 and 48 h after 
administration. Urine was collected at the same 
time intervals. The remainder of the urine was 
collected for 48 h in a tank and stored at -20°C, 
pending isolation.
2.4. Sample treatment
Plasma samples (200 /¿I) were deproteinized 
with acetonitrile (1:1, v/v), centrifuged at 3000 g 
for 5 min and 50 ¿il of the supernatant were 
injected on to the column.
Urine samples were centrifuged at 3000 g, the 
supernatant was diluted 1:5 with 0.6% acetic acid 
(AcOH) and 50 /¿I were injected on to the 
column.
25. Gradient HPLC determination o f S and 
metabolites
The HPLC system consisted of a Marathon 
autosampler (Separations, Hendrik Ido Am- 
bacht, Netherlands), a Spectra System P 4000 
quaternary gradient pump, a Spectroflow 757 UV  
detector (Separations) and a Hitachi D2500 
integrator (Merck, Amsterdam, Netherlands).
The column was a Dynamax 60 A, 8 /¿m, 150 
mm X 4.6 mm I.D. (Meyvis, Bergen op Zoom, 
Netherlands) with a guard column (15 mm X 4.6 
mm I.D.), packed with 8-/xm C8 reversed-phase 
material (Meyvis).
The mobile phase was a mixture of acetonitrile 
and a mixture of 0,5% AcOH plus 0.5 g/l of 
AcONH4 (pH 3.3). At time t -  0, the mobile 
phase consisted of 0% acetonitrile and 100% 
(v/v) AcOH-AcONH4. During the following 5 
min, the mobile phase was changed linearly until 
it attained a composition of 10% acetonitrile and 
90% AcOH-AcONH4. From 5 to 18 min it was 
changed to 18% acetonitrile and 82% AcOH- 
AcONH4. At 18 min, the mobile phase was 
changed within 1 min to the initial composition, 
followed by equilibration for 4 min. The flow- 
rate was 1.5 ml/min. The effluent was monitored 
at 273 nm.
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2.6. Isolation o f the metabolites from urine
Column chromatography
Two litres of monkey urine (48 h, pH 9.3) was 
adjusted to pH 5.0 and allowed to stand over­
night for precipitation of endogenous urates. 
Celite 545 (40 g) was added to the urine and the 
suspension was filtered. The pH of the filtrate 
was adjusted to 5.0.
A preparative column (40 cm X 6 cm I.D., 
packed with 1 kg of XAD-2) was rinsed with 2 1 
of methanol, 2 1 of water and 1 1 of 0.2 M 
KH2P 0 4 buffer (pH 5.0). Thereafter, 11 of urine 
was passed through the column, followed by 2 1 
of the 100-fold diluted phosphate buffer (pH 
5.0). The column was dried by air suction for 10 
min.
Elution of the column was carried out with 
methanol-water according to the following 
scheme: first, 500 ml of CH30 H -H 20  (20:80, 
v/v) was passed through the column, followed by 
eight fractions of 250 ml with the methanol 
concentration increased in steps of 10% to 100%
CH3OH.
Effluent fractions 1-2  (20:80-30:70, v/v) con­
tained 5-hydroxysulfadiazine glucuronide. Ef­
fluent fractions 2-4  (30:70-50:50, v/v) contained 
5-hydroxysulfadiazine sulfate and fractions 5-7  
(60:40-80:20, v/v) contained the hydroxy metab­
olites 4- and 5-hydroxysulfadiazine.
This procedure was repeated with the second 
litre of urine on a regenerated column, and 
fractions 2-4  and 5-7 from both procedures were 
combined. Methanol was evaporated under re­
duced pressure. The combined fraction 5-7 was 
placed on the column and the gradient elution 
was repeated. Fractions 40:60 and 50:50 con­
tained the sulfate conjugate and fractions 70:30 
and 80:20 both contained the unconjugated hy- 
droxysulfadiazines. Most of the yellow-brown 
urine colour had now been removed, together 
with the parent compound and its N4-acetyl 
conjugate.
Preparative high-performance liquid 
chromatography
The volume of the isolated fraction containing 
the hydroxysulfadiazines from the preparative
column was concentrated to 100 ml by evapora­
tion under reduced pressure (Rotavapor), and 
acidifed with 5 M HC1 to pH 2.0 in order to 
prevent precipitation of the hydroxysulfa­
diazines.
The preparative HPLC system consisted of a 
Model 302 sample pump (Gilson, Meyvis, 
Bergen op Zoom, Netherlands), two Gilson 
Model 305 gradient pumps, a Model 811 B 
dynamic mixer, a Kratos Model 757 UV detector 
(Separations), a Model 2211 Superrac fraction 
collector (LKB, Woerden, Netherlands) and a 
BD7 recorder (Kipp & Zonen, Delft, Nether­
lands). The column was a Cg, 8-jj.m particle size, 
250 mm x 10 mm I.D., Rainin Dynamax 60 A  
column (Meyvis). The mobile phase consisted of 
1% acetic acid in water-acetonitrile (85:15, v/v). 
The flow-rate was 4.7 ml/min and absorbance 
peaks were detected at 271 nm.
Concentration of the separated metabolites 
was carried out on an IKA Rotavapor (Janke 
and Kunkel, Staufen, Germany) equipped with a 
Trivac vacuum pump (Leybold-Heraeus, Woer­
den, Netherlands). Two crude samples containing 
40H - and SOHsulfadiazine, respectively, were 
collected.
2.7. Final purification by preparative HPLC
4-Hydroxy sulfadiazine (40H )
For isolation, the mobile phase was 
acetonitrile-1% AcOH (18:82, v/v). The col­
lected sample was concentrated to 20 ml under 
reduced pressure with the Rotavapor, then fur­
ther reduced in volume to 0.5 ml in a smaller 
flask. The final volume of 0.5 ml was transferred 
to a small tube for freeze-drying.
5-Hydroxysulfadiazine (50H )
For isolation, the mobile phase was tetra- 
hydrofuran (THF)-1% AcOH (12:88, v/v). The 
collected sample was concentrated to 20 ml 
under reduced pressure with the Rotavapor, then 
further reduced in volume to 0.5 ml in a smaller 
flask. The final volume of 0.5 ml was transferred 
to a small tube for freeze-drying.
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5-Hydroxysulfadiazine sulfate ( S O H s u l f )
For the first isolation, the mobile phase was 
acetonitrile-1% AcOH, starting at 8:92 (v/v) and 
changed linearly in 18 min to 26:74.
For the second isolation, the mobile phase was 
methanol-water (4:6, v/v).
For the third isolation, the mobile phase was 
acetonitrile-1% AcOH, starting at 12:88 (v/v) 
for 10.5 min, then changed in 1 min to 26:74.
For the final isolation, the mobile phase was 
acetonitrile-water (4:6, v/v).
The collected sample was concentrated to 20 
ml under reduced pressure with the Rotavapor, 
then further reduced in volume to 0.5 ml in a 
smaller flask. The final volume of 0.5 ml was 
transferred to a small tube for freeze-drying.
5-Hydroxysulfadiazine glucuronide (50Hgluc)
For the first isolation, the mobile phase was 
acetonitrile-1% AcOH, starting at 10:90 (v/v) 
and changed linearly in 16 min to 26:74.
For the second isolation, the mobile phase was 
THF-1% AcOH (12:88, v/v).
For the third isolation, the mobile phase was 
methanol~l% AcOH starting at 10:90 (v/v) and 
changed linearly in 15 min to 25:75.
The collected sample was concentrated to 
dryness under reduced pressure with the 
Rotavapor (43 mg).
2.8. Identification o f the metabolites
Mass spectrometry
A V G  7070E double-focusing mass spectrome­
ter was used (Fisons Instruments, Weesp, Nether­
lands). Electron impact (El) ionization (70 eV) 
and fast atom bombardment (FAB) (matrix 
nitrobenzyl alcohol, xenon 8 keV, acceleration 
voltage 6-7 kV) were performed.
Nuclear magnetic resonance spectrometry
’H NMR spectra were recorded on a Bruker 
AM 400 spectrometer (400 MHz, Fourier trans­
form (Bruker, Wormer, Netherlands) on solu­
tions in CD3OD-CDCI3 (internal standard 
Me4Si). 13C NMR spectra with *H decoupling 
were recorded with a Bruker AM 400 spectrome­
ter operating at 100.6 MHz on solutions in
CD30D-CDC13 (internal standard Me4Si). 
Chemical shift values are reported as S values 
relative to Me4Si as internal standard. 
Deuteromethanol and deuterochloroform were 
used as solvents.
Infrared spectrometry 
Infrared spectra in KBr were recorded on a 
Perkin-Elmer 881 (Gouda, Netherlands) Model 
881 infrared spectrophotometer.
Melting point 
Melting points were recorded with a melting 
point apparatus (Biichi, Flawil, Switzerland).
2.9. Deconjugation
Deconjugation reactions with /3-glucuronidase 
[urine-/? glucuronidase-buffer (1:1:8, v/v/v), 9 
days, 37°C] were carried out. Four different ¡3- 
glucuronidase enzymes were tested (all from 
Sigma, St. Louis, MO, USA): (A) 20 000 U/m l 
/3-glucuronidase type B1 (bovine liver, Cat. No. 
G-0251) in phosphate buffer at pH 5.0; (B) 
120 600 U/ml /3-glucuronidase type H2 (Helix 
pomatia, Cat. No. G-0876) in phosphate buffer at 
pH 5.0; (C) 100000 U/m l /3-glucuronidase type 
LII (lyophilized powder from limpets Patella 
vulgata, Cat. No. G-8132) in phosphate buffer at 
pH 3.8; and (D) 20000 U/ml /3-glucuronidase 
type VIIA (Escherichia coli, Cat. No. G-7646) in 
phosphate buffer at pH 6.8.
Deconjugation with arylsulfatase was carried 
out with 19 U/m l sulfatase VI (Aerobacter 
aerogenes; Sigma, Cat. No. S-1629) in Tris solu­
tion of pH 7.1.
Deconjugation reactions with 5 M HC1 [urine- 
HC1 (1:1, v/v), 75°C, 1 h] were carried out.
2.10. Limits of quantification
The limits of detection in water and determi­
nation of sulfadiazine and its metabolites in 
plasma and urine were determined at a signal-to- 
noise ratio of 3.
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2.11. Standard solutions
Standard solutions of S and metabolites were 
prepared as follows: S 10.9 mg/ml in dimethyl- 
formamide (DMF), N 4 3.55 mg/ml in DMF, 
40H  1.16 mg/ml in DMF-0.1 M  HC1 (1:1, v/v), 
SOH 1.78 mg/ml in 0.1 M  HC1, SOHgluc 1.78 
mg/ml in water and SOHsulf 2.0 mg/ml in water.
2.12. Recovery
A calibration graph for four concentrations 
(0.5-60 /Ag/ml) of S and its metabolites in 0.9% 
NaCl solution was compared with a calibration 
graph for the same concentrations in plasma. All 
samples were treated with acetonitrile (1:1, v/v).
2.13. Pharmacokinetics
The pharmacokinetic parameters were calcu­
lated using the MediWare computer package [7].
3. Results
3.1. Identification
Metabolites of S were detected (Fig. 1 and 
Table 1) in a urine sample from a human 
volunteer after oral intake of 500 mg of S and in 
urine from a Rhesus monkey treated with 50 
mg /kg of S orally. Four metabolites of S were 
isolated from the monkey urine sample: 40H , 
5OH, SOHgluc and SOHsulf. The isolated com­
pounds were identified as follows.
4-Hydroxysulfadiazine 
The El mass spectrum of 4-hydroxy- 
sulfadiazine (C10H 10N 4O3S, Mr 266) shows m/z, 
relative intensity, as follows: 267 [M+ +1], 
12.1%; 266 [M+], 100%; 201,17.9%; 202, 23.2%; 
109,12.3%; 108, 44.3%, 93,11.6%; 92, 79.5%; 28, 
70.5%.
The El mass spectrum of sulfadiazine 
(C10H 10N4O2S, Mr 250) shows m/z, relative 
intensity, as follows: 251 [M+ + l], 0.14%; 250 
[M+], 0.06%; 186,100%; 109,11.9%; 108,19.6%; 
93, 37.9%; 92, 51.6%.
Table 1
Retention times and capacity factors of sulfadiazine and its 
metabolites and conjugates
Compound rR (min) k*
'o 1.80
SOHgluc 6,99 2.88
40H 9.85 4,47
Hippuric acid 11.35 5,31
50H 12.00 5.67
SOHsulf 12.70 6.06
S 12.70 6.06
N* 15.56 7.64
Introduction of a hydroxyl group in the sulfadiazine structure 
at the 4-position reduces the capacity factor by a factor of 
0.74, whereas at the 5-position the reduction factor is 0.94. 
Introduction of an acetyl group in the sulfadiazine structure 
increases the capacity factor by a factor of 1,26. Introduction 
of a glucuronide group in 50H  reduces the capacity factor by 
a factor of 0.51, while introduction of a sulphate group has a 
smaller effect, with a reduction factor of 0.89. Hippuric acid is 
an endogenous compound present in urine.
The NMR spectrum in CD3OD-CDCl3 (3:1, 
v/v) is 8 = 7.48 ppm (2H, d, Ha + Ha., Jib =  8.4 
Hz); 7.48 ppm (1H, d, Hc, Jce. = 7.6 Hz); 6.57 
ppm (2H, d, Hb + Hb., / ab = 8.8 Hz); 5.90 ppm 
(2H, s, NH2); 5.70 ppm (1H, d, Hc„ 7CC. =7.6  
Hz); 3.16 ppm (1H, d, OH).
The melting point is 269-270°C with decompo­
sition. The IR spectrum shows the sulfone moie­
ty at 1600 and 1630 nm.
5-Hydroxysulfadiazine
The El mass spectrum of 5-hydroxy- 
sulfadiazine (C10H 10N4O3S, Mr 266) shows mlz,  
relative intensity, as follows: 267 [M+ +1], 
0.65%; 266 [M+], 0.62%; 203,13.7%; 202,100%; 
201, 80.9%; 156, 14.3%, 109, 3.5%; 108, 45.2%; 
93, 11.6%; 92, 94.2%; 65, 65.3%.
The positive-ion FAB mass spectrum shows
mlz,  relative intensity, as follows: 267 [M +  H +], 
100%; 289 [M+ + Na], 25%; 533 [2M + H +], 4%; 
555 [2M + Na+], 4%.
The NMR spectrum in CD30D-CDC13 (3:1, 
v/v) is S = 8.02 ppm (2H, s, Hc + Hd); 7.69 ppm 
(2H, d, Ha + H,., = 8.8 Hz); 6.62 ppm (2H, d, 
Hb + Hb„ / ab = 8.8 Hz).
The melting point is 182-183°C with decompo-
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sition. The IR spectrum shows the sulfone moie­
ty at 1600 and 1630 nm.
The NMR spectrum of sulfadiazine in 
CD3OD-CDCI3 (3:1, v/v) is 8 -  8.39 ppm (2H, 
d, H + Hc., / cd = 4.8 Hz); 7.76 ppm (2H, d, Ha +
= 7.0 Hz); 6.88 ppm (1H, t, Hd,
4.8 Hz); 6.62 ppm (2H, d, Hb + Hb„ J
H...
*^ c'd " ab
7.0 Hz). The melting point is 252-256°C.
5-Hydroxy sulfadiazine sulfate 
The positive-ion FAB mass spectrum of 5- 
hydroxysulfadiazine sulfate (C10H i0N4O6S2> Mr 
345) shows m lz , relative intensity, as follows: 
347, 5%; 345, 4%; 369, 7% [M+ + Na].
The NMR spectrum in CD3OD is 5 = 8.28 
ppm (2H, s, H c + Hc0; 7*63 ppm (2H, d, Ha + 
Ha'> a^b ^ 8.7 Hz); 6.65 ppm (2H, d, Hb + Hb,,
7ab = 8.7 Hz).
Acid hydrolysis in 5 M HC1 at 50°C for 2 h 
resulted in 5-hydroxysulfadiazine. Treatment of 
the isolated compound with arylsulfatase VI 
resulted in 5-hydroxysulfadiazine.
The IR spectrum shows the sulfone moiety at 
1640 nm. The melting point is 169°C with de­
composition,
standard
blank
monkey
AOH SOH
ro T10 I15 T20 *125 min
Fig. 2. Chromatograms of Rhesus monkey plasma containing 
sulfadiazine (S) and its metabolites, a blank monkey plasma 
and the isolated reference compounds. The concentrations of 
the compounds in the standard are S 52.6, 40H  5,6 ,50H  8.6, 
50Hgluc 5.7, SOHsulf 7.1 and N4 9.0 /¿g/ml.
3.2. Other data
Table 1 shows the retention times and the 
capacity factors of parent drug and its metabo­
lites.
Fig. 2 shows the chromatograms for monkey 
plasma with blank and standards and Fig. 3
Ha + Ha„ ; ab
H y, JBb =
5-Hydroxysulfadiazine-O-glucuronide
The positive-ion FAB mass spectrum shows 
m l z , relative intensity, as follows: 443 [M + H*], 
20%; 465 [M + N a+], 12%; base peak 273,100%.
The NMR spectrum in CD3OD at 40°C is 
8 = 8.30 ppm (2H, s, H c + Hc,); 7.71 ppm (2H, d,
= 8.8 Hz); 6.63 ppm (2H, d, Hb + 
8.8 Hz); 4.86 ppm (1H, m, Ht); 3,94 
ppm (1H, d, H5, / 45 = 10 Hz); 3.59 ppm (1H, m, 
H4); 3.46 ppm (2H, m, H2 + H3).
Acid hydrolysis in 5 M  HC1 resulted in 5- 
hydroxysulfadiazine. Treatment of the isolated 
compound with /3-glucuronidase (system C) for 1 
h at 37°C resulted in 5-hydroxysulfadiazine. The 
melting point is 167°C with decomposition; there 
is a phase and colour transition at 104-105°C
from yellow to rose-red.
The IR spectrum shows the sulfone moiety at 
1600 and 1630 nm, the glucuronide carbonyl 
moiety at 1730 nm and a broad maximum 3200- 
3450 nm of the glucuronyl group.
human
monkey
I
25min
Fig. 3. Chromatograms of a Rhesus monkey and human 
plasma sample containing sulfadiazine (S) and its metabo­
lites. 5-Hydroxy sulfadiazine with its conjugates is not present 
in human plasma. The concentrations of the compounds in 
the human plasma sample are S 12.6, 40H  0.6 and N4 1.5 
/¿g/ml. The concentrations of the compounds in the monkey 
plasma sample are S 57.7, 4 0 H  1.1, 50H  1.6, SOHgluc 2.3, 
SOHsulf 2.1 and N4 2.2 /z-g/ml.
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Fig. 4. Chromatograms of Rhesus monkey urine containing 
sulfadiazine (S) and its metabolites, a blank monkey plasma 
and the isolated reference compounds. The concentrations of 
the compounds in the urine are S 653, 4 0 H  32.4, 50H  10.2t 
SOHgluc 25.7, 50Hsulf 13.4 and N 4 85.5 /¿g/ml.
compares the chromatograms for monkey and 
human plasma after an oral dose of sulfadiazine. 
The chromatograms show the presence of S and 
its metabolites. Figs. 4 and 5 show chromato­
grams for monkey and human urine and a urine 
sample after oral administration of S,
Table 2 shows the equations for the calibration
f1
F '
1 ;
fi
i ,
f *
!! ;! ♦ • '1
n4
40H
50 H
human
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SOHgluc SOHsulf
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Fig. 5. Chromatograms of Rhesus monkey and human urine 
containing sulfadiazine (S) and its metabolites. 5-Hydroxy- 
sulfadiazine and its conjugates are not present in human 
urine. The concentrations of the compounds in the human 
urine sample are S 67.5, 40H  12.3 and N< 85.5 f ig lml  The 
concentrations of the compounds in the monkey urine sample 
are given in Fig. 4.
graphs for S and its metabolites in plasma and 
urine, Table 3 shows the limits of detection in 
water and limits of quantification in plasma and 
urine of S and its metabolites. Samples at pH 5 
and kept in the dark were stable in the auto­
sampler of the HPLC for 24 h.
Table 2
Calibration graphs for sulfadiazine and its metabolites
Compound Concentration
(/xg/ml)
Curve8 Correlation 
coefficient (r)
Plasma
40H 0.20-2.32 y  = 702* + 41.2 0.9981
50H 0.37-3.56 y  = 420* -  30.4 0.9989
SOHgluc 0.33-2.36 y  = 500* -  3.62 0,9981
50H sulf 0.57-4.00 y  = 243jc + 20.5 0.9960
S 0.31-218 1! ■u £ 1 0.9999
H 0.40-7.1 y «  379* + 10.7 0.9998
Urine
40H 0.6-116 y  =  93.2* + 53.1 0.9997
50H 0.8—356 y = 78.6* + 77.8 0.9982
50Hgluc 0.8-118 y «  89.3* 4- 73.0 0.9997
50Hsulf 1.1-50 y  «  65.0* + 77.8 0.9982
s 0.8-2180 y  = 95.7* + 466 0.9997
N. 0.8-187 y  *  75.5* + 2.4 0.9997
*y -  Peak height (integration units) and * = concentration (¿ig/ml).
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Table 3
Recovery and limits of detection and quantification of sulfadiazine and its metabolites
Compound Detection limit’ 
in water 
(/ig /m l)
Quantification limit1 (¿ig/ml)* Recovery in plasma (n =  4) (%)
Urine Plasma Mean C.V.
40H 0.07 0.6 0.20 95.6 4.1
50H 0.12 0.8 0.37 92.8 8.3
50Hgluc 0,11 0,8 0.33 101,7 1.3
SOHsulf 0,11 1,1 0,57 96,6 4.9
S 0.08 0,8 0.31 98.4 3.5
N< 0.12
#
0.8 0.40 84.3 6.1
" Detection limit in water; quanfitication limit in the biological matrix.
Tables 4 and 5 show the intra- and inter-day concentration-time curve and renal excretion 
variations, respectively, for S and its metabolites rate-time profiles for S and its metabolites after 
in plasma, and Tables 6 and 7 show those for S a single oral administration of 500 mg of S to one 
and its metabolites in urine, male volunteer.
Fig. 6 shows an example of the plasma con- Table 8 summarizes some pharmacokinetic 
centration-time curves for S and its metabolites parameters of S calculated from the plasma and 
in a Rhesus monkey and Fig* 7 shows the plasma urine concentrations of the parent drug and its
Table 4
Inter-day coefficients of variation (C.Y) for spiked sulfadiazine and its metabolites in human plasma (n = 4, in vitro)
Compound
►
Concentration
added
(/ig /m l)
Concentration
measured
(¿Lg/ml)
Precision 
(C.V., % )
Accuracy
(%)
40H 2.32 2.64 11.6 13.8
50H 3.56 3.56 3.0 0
50Hgluc 2.36 2.34 5.2 0.8
50H sulf 4,00 3.76 15.1 6.0
S 218 222 2.4 1.7
N< 7.10 6.93 1.0 2.4
40H 1.16 1.26 14.6 8.6
5 OH 178 1.76 3.3 1.1
SOHgluc 1.18 1.16 3.3 1.7
50H sulf 2.00 1.80 13.2 10.0
S 109 111 3.4 1.4
3.55 3.45 2.7 2.8
40H 0.56 0.61 16.4 7.1
5 OH 0.86 0.78 9.1 9.3
50Hgiuc 0.57 0.58 12.8 1.8
SOHsulf 0.32 n.d. — —
S 5.26 5.63 9.6 7.0
0.90 0.83 12.2 7.8
Table 5
Intra-day coefficients of variation (C.V.) for spiked sulfadiazine and its metabolites in human plasma (n = 4, in vitro)
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Compound Concentration Concentration Precision Accuracy
added measured (C.V, %) (%)
(/ig /m l) (Mg/ml)
40H 2.32 2,27 4.8 2.2
50H 3.56 3.55 1.7 0.3
50Hgluc 2.36 2.42 3.5 2.5
50Hsulf 4.00 4.01 4.4 0.0
S 218 216 1.1 1.0
N< 7.10 6.89 0.6 3.0
40H 1.16 1.11 3.6 4.4
50H 1.78 1.82 0.8 2.2
50Hgluc 1.18 1.15 3.5 2.5
50H sulf 2.00 1.98 7.6 1.0
S 109 106 1.1 2.6
n 4 3.55 3.41 1.3 4.0
40H 0.56 0.60 10.0 7.1
50H 0.86 0.83 9.0 3.5
50Hgluc 0.57 0.62 8.3 8.8
50H sulf 0.32 n.d. —
S 5.26 5.71 4.6 8.6
N, 0.90 0.93 12.7 3.3
plasma cone jjg/ml
100-
Rhesus Monkey
50 mg/kg Sulfadiazine p.o.
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Fig. 6. Plasma concentration-time curve for sulfadiazine (S), 
N4-acetyl sulfadiazine (N4), 4-hydroxysulfadiazine (40H ) and 
5-hydroxysulfadiazine (50H ) and its glucuronide (SOHgluc) 
and sulfate (50Hsulf) conjugates in a Rhesus monkey after 
an oral dose of 50 mg /kg of sulfadiazine.
1000-j piuma cooc pfl/ml ' 
rwMl *xcr t t f  }*g/min
500 mg Sulfadiazine p.o
100-
N4 35.1 X
& 45.8 %
«  40H 13.3 %
S t., 16.8 h
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Fig. 7. Plasma concentration-time curve and renal excretion 
rate-time profiles for sulfadiazine (S)> N4-acetylsulfadiazine 
(N4) and 4-hydroxysulfadiazine (40H ) in a human volunteer 
after an oral dose of 500 mg of sulfadiazine (6 mg/kg).
Table 6
Inter-day coefficients of variation (C.V.) for spiked sulfadiazine and its metabolites in human urine {n ~  4, in vitro)
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Compound Concentration Concentration Precision Accuracy
added measured (C.V., %) (%)
(¿tg/ml) (/ig/m l)
40H 116.0 113.0 1.8 2.5
5 OH 89.0 93.8 6.5 5.4
SOHgluc 118.0 116.0 1.4 1.4
50H sulf 70.0 64.9 2.3 7.3
S 215.0 217.0 3.9 1.1
n 4 178.0 177.0 3.7 0.4
40H 58.0 56.4 2.7 2.8
50H 44.5 44.2 2.5 0.7
SOHgluc 59.0 58.4 2.1 1.0
SOHsulf 35.0 33.5 1.5 4.3
S 107.0 110.0 3.1 2,2
n 4 89.0 89.8 2.6 0.9
40H 14.5 14.8 4.1 2.1
SOH 11.1 11.5 7.0 3.6
SOHgluc 14.8 14.2 11.3 4.2
SOHsulf 8.8 8.6 12.8 2.3
S 26.9 27.8 3.6 3.3
N< 22.3 22.7 2.6 1.8
40H 5.8 5.9 10.1 1.7
SOH 4.5 4.3 5.8 4.4
SOHgluc 5.9 6.0 12.5 1.7
50sulf 3.5 2.9 12,4 17.1
S 10.8 10.5 4.4 2.8
n 4 8.9 8.7 5.3 2.2
metabolites in the pilot experiment after a single 
oral administration of 500 mg S to the human 
volunteer.
4. Discussion
The presence of metabolites of sulfadiazine 
and its availability for isolation strongly depends 
on the species. For instance, if only human urine 
had been investigated, 5-hydroxysulfadiazine 
with its conjugates would not have been detected 
and isolated.
The metabolites 4- and 5-hydroxysulfadiazine 
have already been described [4]. Vree and co­
workers isolated the metabolite from the urine of 
dogs [5] and excreta of fresh water turtles 
Pseudemys scripta elegans by preparative TLC
[8]. Dog’s urine is relatively easy to analyse, 
because dogs are unable to acetylate sulfon­
amides [5]. Excreta of turtles diluted in tank 
water give clean chromatograms containing 4- 
and 5-hydroxysulfadiazine [8]. Other reported 
conjugates of sulfadiazine included the deami- 
nated metabolites [9]. O-Glucuronides can be 
hydrolysed by /3-glucuronidases; of the four /?- 
glucuronidase systems tested, systems C and D  
were the most active for O-deglucuronidation.
The 5-hydroxy group in the pyrimidine ring in 
the meta position to the nitrogen atoms acts as a 
phenolic hydroxyl group and is extremely suscep­
Table 7
Intra-day coefficients Of variation (C.V.) for spiked sulfadiazine and its metabolites in human urine (n =  4, in vitro)
Compound Concentration Concentration Precision Accuracy
added measured (C.V., %) (%)
(/tg/ral) (/tg/m l)
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40H 116.0 113.0 1.5 2.2
SOH 89.0 88.4 0.9 0.7
SOHgluc 118.0 115.0 0.9 2.5
SOHsulf 70.0 64.3 1.0 8.1
S 215.0 214.0 0.9 0.2
n 4 178.0 171.0 0.7 3,9
40H 58.0 58.4 1.1 0.7
SOH 44.5 45.7 1.5 2.7
SOHgluc 59.0 59,0 1.2 0.0
SOHsulf 35.0 33.8 0.9 3.4
S 108.0 111.0 1.0 3.3
N< 89.0 88.4 0.4 0.7
40H 14.5 15.3 2.5 5.5
SOH 11.1 11.4 3.7 2.7
SOHgluc 14.8 14.7 2.9 0.7
SOHsulf 8.8 9.1 1.3 3.4
S 26.9 27.7 1.8 3.0
n 4 22.3 22.5 1.2 0.9
40H 5.8 6.1 5.4 5.2
SOH 4.5 4.5 10.5 0.0
50Hgluc 5.9 6.7 4.8 13.6
SOsulf 3.5 3.2 5.9 8.6
S 10.8 11.0 2.2 1.9
n 4 8.9 8.7 1.7 2.2
tible to conjugation. The 4-hydroxy group is not 
accessible for conjugation in man, monkey and 
turtle.
Differences in the metabolism of sulfonamides 
between humans and monkeys may be related to 
differences in the rates of metabolism and differ­
ences between the urine pH in the two species.
In man, the urine pH varies between 5 and 7, 
resulting in renal excretion of the parent drug 
(45%), acetylation (35%) and oxidation of sul­
fadiazine (13%). Monkey urine pH varies be­
tween 8 and 9.5, resulting in a similar renal 
excretion of the parent drug (40%), but minimal 
acetylation (8%), which is compensated for by 
enhanced oxidation (50%). A  similar difference 
in the N-glucuronidation was reported earlier;
human urine contained the N,-glucuronide of
sulfamethoxazole [10], which is absent in monkey
urine [11]. Also in humans sulfadimethoxine is 
mainly glucuronidated at the N,-position [12], 
whereas in pigs it is only acetylated at the re­
position [13].
Addition of AcONH4 to the eluent is essential
for a stable retention time of sulfadiazine-O- 
sulfate. Without AcONH4, the retention time 
and the peak shape of the sulfate depend on the
concentration. A similar behaviour was observed
for paracetamol sulfate [14].
In conclusion, the hydroxy metabolites of 
sulfadiazine, 4-hydroxysulfadiazine and 5-hy­
droxysulfadiazine with its corresponding sulfate 
and glucuronide conjugate were isolated from
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Table 8
Pharmacokinetic parameters for sulfadiazine and its metabolites and conjugates from a healthy human subject and from a Rhesus 
monkey after a single oral administration of sulfadiazine
Parameter Value
Subject A Monkey
Gender Male Female
Body mass (kg) 85 10
Acetylator status Slow
Dose (rag) 500 50*
Compound S 40H S
Bioavailability, F (%) 94.2 b 35.1 13.3 100
(M g/«I) 16.9 1.54 0.64 46.2
'm, W 3.7 10.1 7.738
12 absorption (^) 0.49 1.25
*1/2 formation (^) 2.7 2.0
*1/2 (h) 16.6 20.7 17.5 5,9
MRT S (h) 25.9 34.7 28.8 10.6
Total body clearance (1/h) 1.06 3.84 3.11 0.084'
Volume of distribution (1) 25.3 84.7 78.2 0.71*
Renal clearance (1/h) 0.61 3.35 3.44 0.071
Percentage of dose
excreted (mol-%) 45.8 35.1 13.3 39.7
Total (%) 94.2b 100”
1 mg/kg, values/kg.
b Renal excretion (mol-%) 40H  19.9%, 50H  17.4%, 50Hgluc 9.1%, 50Hsulf 5.9%, S 39.7%, N4 8.0%.
monkey urine and their structures could be 
confirmed as corresponding to those reported in 
the literature.
References
[1] J.S. Remington and G. Desmonts, in J.S. Remington and 
J.O. Klein (Editors), Infectious Diseases of the Fetus 
and Newborn Infant, W.B. Saunders, Philadelphia, 3rd 
ed., 1990, p. 89.
[2j M.A. Sande, J.E. Kapusnik-Uner and G.L. Mandell, in 
A. Goodman Gilman, T.W. Kali, A.S. Nies and P. Taylor 
(Editors), The Pharmacological Basis of Therapeutics, 
Pergamon Press, New York, 8th ed., 1990, p. 1018.
[31 A J.A.M. van der Ven, P.P. Koopmans, T.B. Vree and 
J.W.M. van der Meer, Lancet, 338 (1991) 431.
[4] C.W. Sigel, in G.H. Hitchings (Editor), Inhibition of 
Folate Metabolism and Chemotherapy. The Origins and 
Uses of Co-trimoxazole, Springer, Berlin, 1983, pp. 163-
184.
[5] T.B. Vree and Y.A. Hekster, Antibiot. Chemother,, 34 
(1985) 1.
[6] T.B. Vree and Y.A. Hekster, Antibiot. Chemother., 37 
(1987) 1.
[7] J.H. Proost and D.K.F. Meijer, Comput. Biol. Med., 22 
(1992) 155.
[8] T.B. Vree, J.B. Vree, E.W.J. Beneken Kolmer and Y.A. 
Hekster, Vet. Q., 13 (1991) 218.
[9] J.L. Woolley, A. Ragouzeous, D.A. Brent and C.W. 
Sigel, in J.D. Nelson and C. Grassi (Editors), Current 
Chemotherapy and Infectious Disease, American Socie­
ty for Microbiology, Washington, DC, 1980, p. 552.
[10] T.B. Vree, A.J.A.M. van der Ven, C.P.W.G.M. Verwey- 
van Wissen, E.W.J. van Ewijk-Beneken Kolmer, A.E.M. 
Swolfs, P.M. van Galen and H. A  matdjais-Groenen, J. 
Chromatogr., 658 (1994) 327.
[11] E. Schoondermark-van de Ven, unpublished work.
[12] T.B. Vree, E.W.J. Beneken Kolmer, M.Martea, R. Bosch 
and M. Shimoda, J. Chromatogr., 526 (1990) 119.
[13] M. Shimoda, T.B. Vree, E.W.J. Beneken Kolmer and 
Th.H.M. Arts, Vet QM 12 (1990) 87.
[14] T.B. Vree et al., unpublished results.
